1 Alemtuzumab (anti-CD52;
Campath 1-H) depletes both host and donor T cells when u
2 Alemtuzumab 30 mg (
Campath 1-H) was used for preconditioning followed by lo
3 tored the outcome of 2,582 transplants using
CAMPATH-
1 (CD52) antibodies to deplete lymphocytes from
4 like many other methods of T-cell depletion,
CAMPATH-
1 antibodies also deplete B lymphocytes.
5 Campath-
1 antibodies are directed against the surface an
6 ificity and antigen affinity of this pair of
CAMPATH-
1 antibodies for CD52.
7 CAMPATH-
1 antibodies have a long and successful history
8 rface glycoprotein CD52, commonly called the
CAMPATH-
1 antigen.
9 The
CAMPATH-
1 family of antibodies are able systematically t
10 al risk of lymphoproliferative disease using
CAMPATH-
1 for depletion of donor lymphocytes was up to 1
11 that removed both T and B cells, such as the
CAMPATH-
1 monoclonal antibody or elutriation (P =.009).
12 tions were more common in patients receiving
Campath 100 mg in vivo, but delayed CD4+ recovery was th
13 treated with the CD52 monoclonal antibodies
CAMPATH-
1G (rat IgG2b) or its humanized derivative, CAMP
14 Murine forms,
Campath-
1G and Campath-1M, have been utilized extensivel
15 ntibody, the original therapeutic monoclonal
CAMPATH-
1G and its humanized counterpart CAMPATH-1H, int
16 Crystals of
CAMPATH-
1G have translational pseudo-symmetry.
17 bone marrow depleted with CAMPATH-1M, but no
CAMPATH-
1G in vivo; and (2) 459 patients reported to the
18 Using
CAMPATH-
1G to deplete residual host lymphocytes is a sim
19 in vitro depletion of the graft and an IgG (
CAMPATH-
1G) for in vivo depletion of the recipient befor
20 Campath 1H (0.3 mg/kg) was administered in four doses: P
21 noma cells (which express Ep-Cam but not the
Campath 1H antigen) followed by incubation of the cells
22 By contrast, the enzyme-
Campath 1H conjugate was without effect.
23 f this research was to study the efficacy of
campath 1H in combination with low-dose tacrolimus immun
24 renal allograft recipients were treated with
Campath-
1H (0.3 mg/kg) on days 0 and 4 postoperatively,
25 CAMPATH-
1H (30 mg) was administered intravenously 3 time
26 Kidney transplant patients given
Campath-
1H (Alemtuzumab) immunodepletion therapy and lon
27 Campath-
1H (alemtuzumab) is the most effective monoclona
28 We evaluated the efficacy of
Campath-
1H (alemtuzumab; a humanized monoclonal antibody
29 -1G (rat IgG2b) or its humanized derivative,
CAMPATH-
1H (human immunoglobulin G1).
30 rabine (range, 4-10 courses) and 16 weeks of
Campath-
1H (range, 8-32 weeks) were treated.
31 The administration of alemtuzumab (
Campath-
1H [C1H]; Berlex Laboratories, Montville, NJ) at
32 inical trials and manageable toxicities make
Campath-
1H an appealing agent in the treatment of hemato
33 ransplantation from 24 patients treated with
Campath-
1H and sirolimus and tested for serum creatinine
34 Ten (42%) of the 24 patients treated with
Campath-
1H and sirolimus produced HLA antibodies.
35 The
campath-
1H antibody has activity in chronic lymphocytic
36 atients who received the lymphocytotoxic mAb
CAMPATH-
1H between 1991 and 1994 in the United Kingdom w
37 sults in 39 patients with T-PLL treated with
CAMPATH-
1H between March 1993 and May 2000.
38 The
CAMPATH-
1H binding site is highly basic; ionic interacti
39 Analysis of the
CAMPATH-
1H binding site reveals that in contrast to most
40 Prolonged treatment with
CAMPATH-
1H can lead to patient anti-idiotype responses w
41 Campath-
1H causes the immune response to change from the
42 Campath-
1H combined with fludarabine is a highly promisi
43 We present the 1.9 A structure of the
CAMPATH-
1H Fab complexed [corrected] with an analogue of
44 Treatment with
Campath-
1H for 4 weeks led to a striking prolongation of
45 The VL domains of adjacent molecules of
CAMPATH-
1H form a symmetric dimer within the crystals wi
46 The infectious complications noted in the
Campath-
1H group were compared with a historical group o
47 The genetically engineered
Campath-
1H has been utilized in the treatment of lymphom
48 These results demonstrate that
Campath-
1H has therapeutic efficacy on ATL in vivo in th
49 g monoclonal antibodies such as rituximab or
Campath-
1H in combination with fludarabine offer the opp
50 These studies suggest that
Campath-
1H in conjunction with rapamycin monotherapy ret
51 ies, such as CD3 immunotoxin in primates and
CAMPATH-
1H in humans, has demonstrated that long-term gr
52 udy provides support for a clinical trial of
Campath-
1H in the treatment of patients with T-cell leuk
53 The main tumor killing mechanism with
Campath-
1H in vivo involves FcRgamma-containing receptor
54 t (P = 0.05), and being a child who received
Campath-
1H induction (P = 0.03).
55 Patients who received
Campath-
1H induction did not have an increased incidence
56 In this study, we determined whether
Campath-
1H induction followed by sirolimus monotherapy i
57 Campath-
1H induction for renal transplantation appears t
58 We began using 30 mg
Campath-
1H intravenously for induction therapy in May 20
59 Campath-
1H is an active drug in T-PLL patients for whom
60 The conclusion is that
CAMPATH-
1H is an effective therapy in T-PLL, producing r
61 Campath-
1H may be administered intravenously or subcutan
62 ade the infectious morbidity associated with
Campath-
1H more manageable.
63 on ATL in vivo in that the life span of the
Campath-
1H treatment group was comparable with that of m
64 plantation were expanded, and induction with
Campath-
1H was introduced.
65 urvival of mice receiving 4 weeks of 4 mg/kg
Campath-
1H was significantly longer than that of the gro
66 We report the combination of
Campath-
1H with fludarabine in patients with CLL refract
67 safety, and clinical benefit of alemtuzumab (
Campath-
1H) for patients with relapsed or refractory B-c
68 Alemtuzumab (
Campath-
1H) induction with tacrolimus monotherapy has be
69 ither conventional treatment or alemtuzumab (
Campath-
1H) induction.
70 Alemtuzumab (
Campath-
1H) is a humanized IgG1 monoclonal antibody that
71 Alemtuzumab (
Campath-
1H) is a humanized monoclonal antibody (Ab) dire
72 Alemtuzumab (MabCampath,
Campath-
1H) is a lymphocyte-depleting monoclonal antibod
73 Alemtuzumab (MabCampath,
Campath-
1H) is a potent lymphocyte-depleting monoclonal
74 Alemtuzumab (
Campath-
1H) is a powerful antilymphocyte antibody that p
75 g humanized monoclonal antibody alemtuzumab (
Campath-
1H) is highly effective in the treatment of earl
76 chanism of action of alemtuzumab (anti-CD52;
Campath-
1H) remains unclear.
77 te maintenance corticosteroids, alemtuzumab (
Campath-
1H) was used as induction therapy in first cadav
78 d anti-leukocyte (CD52) monoclonal antibody (
Campath-
1H), has illuminated mechanisms that underlie th
79 ntation patients who received a alemtuzumab (
Campath-
1H)-based induction protocol for the incidence o
80 e anti-CD52 monoclonal antibody alemtuzumab (
Campath-
1H).
81 lysis to evaluate the safety and efficacy of
Campath-
1H, an anti-CD52 humanized monoclonal antibody,
82 hat binds to the tumor antigen Ep-Cam, or to
Campath-
1H, an antibody that binds to the T and B cell a
83 treated with fludarabine, cyclophosphamide,
CAMPATH-
1H, and CD34-selected HSCT (8 million CD34+ dono
84 We combined alemtuzumab (
Campath-
1H, Berlex Laboratories, Montville, NJ) and tacr
85 nsisted of the humanized monoclonal antibody
CAMPATH-
1H, fludarabine, and melphalan.
86 nal CAMPATH-1G and its humanized counterpart
CAMPATH-
1H, into which the six complementarity-determini
87 The humanized form,
Campath-
1H, is currently the focus of many clinical tria
88 In an early assessment, the combination of
Campath-
1H, low dosing of tacrolimus and mycophenolate m
89 Alemtuzumab (
Campath-
1H, Millennium Pharmaceuticals, Cambridge, MA) i
90 = 51), and group 3b (April 2001 to present,
Campath-
1H, n = 18) was 44%/32%, 52%/38%, 83%/60%, and 4
91 he first antibody to undergo "humanisation",
CAMPATH-
1H, permits treatment with limited patient anti-
92 Nonmyeloablative allogeneic SCT after
CAMPATH-
1H-containing conditioning is a relatively safe
93 ar leukocytes and monocytes are required for
Campath-
1H-mediated tumor killing in vivo.
94 The most common
Campath-
1H-related adverse events were acute reactions d
95 f acute rejection, the latest 2 treated with
Campath-
1H.
96 induction rate with the human CD52 antibody,
CAMPATH-
1H.
97 pates in only two main-chain interactions in
CAMPATH-
1H.
98 re and for 18 months after a single pulse of
Campath-
1H.
99 the humanised anti-CD52 monoclonal antibody,
Campath-
1H.
100 ined the efficacy and safety of alemtuzumab (
Campath-
1H; Burroughs Wellcome, United Kingdom) in patie
101 ion, which had been frequent in the historic
CAMPATH-
1M group (31%), was largely overcome in the trea
102 An IgM (
CAMPATH-
1M) was used for in vitro depletion of the graft
103 ients who received bone marrow depleted with
CAMPATH-
1M, but no CAMPATH-1G in vivo; and (2) 459 patie
104 Murine forms, Campath-1G and
Campath-
1M, have been utilized extensively in allogeneic
105 esponses to donor antigen were equal between
Campath and control groups.
106 es to authentic TGN1412 but only modestly to
Campath and not to control antibodies such as Herceptin,
107 ys also do not fully delineate mild (such as
Campath)
and severe (such as TGN1412) cytokine storm-ind
108 ty allograft recipients T-cell depleted with
Campath antibodies were evaluated for respiratory virus
109 ty antibodies, broad-specificity antibodies,
Campath antibodies, elutriation, and lectins.
110 Alemtuzumab (MabCampath or
Campath;
Genzyme, Cambridge, MA) is a CD52-specific mono
111 However, the
Campath group displayed a greater response to third part
112 Eight of the 49 (16%) patients in the
Campath group had an infectious complication, compared t
113 CAMPATH monoclonal antibodies were used for T-cell deple
114 oglobulin, and Rituximab (three patients) or
Campath (
one patient), AMR was treated with laparoscopic
115 Interestingly, more
Campath patients (4 of 15) than control patients (0 of 8
116 g humanized monoclonal antibody alemtuzumab (
Campath [
registered trade mark]) significantly reduced t
117 We examined the T-cell responses of
Campath-
treated transplant patients on monotherapy versu